Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
<p dir="ltr">In a cohort of patients with differing severity of COVID-19 disease, including non-survivors, plasma proteomic analysis identified biomarkers of COVID-19 disease progression [1]. The top pathways identified by Shu et al. were those of platelet degranulation and the compl...
محفوظ في:
| المؤلف الرئيسي: | Abu Saleh Md Moin (6189512) (author) |
|---|---|
| مؤلفون آخرون: | Manjula Nandakumar (1545811) (author), Thozhukat Sathyapalan (704787) (author), Stephen L. Atkin (6684368) (author), Alexandra E. Butler (6189536) (author) |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
حسب: Abu Saleh Md Moin (6189512)
منشور في: (2020) -
Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
حسب: Abu Saleh Md Moin (6189512)
منشور في: (2021) -
Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
حسب: Abu Saleh Md Moin (6189512)
منشور في: (2021) -
The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
حسب: Abu Saleh Md Moin (6189512)
منشور في: (2021) -
Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
حسب: Abu Saleh Md Moin (6189512)
منشور في: (2021)